Equities

Galectin Therapeutics Inc

Galectin Therapeutics Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)3.23
  • Today's Change0.09 / 2.87%
  • Shares traded148.56k
  • 1 Year change+93.41%
  • Beta0.6889
Data delayed at least 15 minutes, as of May 17 2024 21:00 BST.
More ▼
Improved Notifications for Markets Data Alerts
Improved Notifications for Markets Data Alerts
Want push notifications for equity price changes and breaking news stories? Let us know here.
 
Existing alertsView our existing alerts
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Cash flow in USDView more

In 2023, Galectin Therapeutics Inc increased its cash reserves by 38.02%, or 7.07m. Cash Flow from Financing totalled 40.03m or -- of revenues. In addition the company used 32.97m for operations while cash from investing was breakeven.
Cash flow per share--
Price/Cash flow per share--
Book value per share-0.9739
Tangible book value per share-0.9739
More ▼

Balance sheet in USDView more

Galectin Therapeutics Inc appears to have a weak balance sheet, highlighted by its negative owner's equity. Additionally, this company's debt load is greater than its assets while day-to-day operations are losing money. Galectin Therapeutics Inc has considerable financial risk.
Current ratio1.77
Quick ratio--
Total debt/total equity--
Total debt/total capital6.24
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.